Overcoming the Challenges of Acute and Chronic GVHD

Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic DiseaseПодробнее

Prevention strategies for acute and chronic GVHD in patients who have undergone transplantationПодробнее

Management of acute and chronic GvHDПодробнее

Management strategies for acute and chronic GvHD following alloSCTПодробнее

Optimizing the outcomes of patients with acute and chronic GvHD & recent updates in this spaceПодробнее

Managing Chronic GVHD: 100 Days After Transplant and BeyondПодробнее

Acute GVHD: Grade, Risk, and ProphylaxisПодробнее

Dr. Cutler on Treatment Options for Acute and Chronic GVHDПодробнее

New Perspectives in Acute and Chronic GVHDПодробнее

Clinical Trials of Itacitinib for Chronic and Acute GVHDПодробнее

Ruxolitinib for Steroid-Refractory Acute GVHDПодробнее

Dr. Cutler on Optimizing Treatment for Acute and Chronic GVHDПодробнее

Allogeneic Transplants & Graft-Versus-Host Disease (GVHD) | Dr. David Miklos, StanfordПодробнее

BMT InfoNet: Gastrointestinal GVHD 2011Подробнее

Chronic Graft versus Host Disease and the Gastrointestinal Tract 2016Подробнее

Vedolizumab for GI acute GvHD prophylaxis after allogeneic transplantationПодробнее

Managing Steroid-Refractory Acute GVHDПодробнее

Dr. Cutler on Remaining Challenges in GVHDПодробнее

Transforming GVHD Treatment: The Mount Sinai Acute GVHD International Consortium (MAGIC)Подробнее